We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Prof
Peter
Hutchinson
+44 (0)1223 336946
pjah2@cam.ac.uk
Dr
Samantha
Lawes
+44 (0)1223 256624
samantha.lawes@addenbrookes.nhs.uk
More information about this study, what is involved and how to take part can be found on the study website.
Post-traumatic seizures in traumatic brain injury patients
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
The majority of patients who suffer a traumatic brain injury (TBI) do not need to stay in hospital overnight. However, some require admission to a specialist hospital, as their injury is more serious. Seizures can be harmful or even fatal, if not treated appropriately. Medications that reduce the risk of seizures are called anti-epileptic drugs (AEDs). However, AEDs have side effects, which can affect patients’ quality of life, memory, concentration and general health.
Patients with seizures after TBI are typically prescribed an AED to prevent further seizures, most commonly phenytoin or levetiracetam. Some doctors favour a short course, whereas others favour a longer course. The first part of the study aims to answer if one approach is better than the other (MAST-DURATION). The second part of the study aims to answer if a 7-day course of either phenytoin or levetiracetam should be used for patients with a serious TBI to prevent seizures from happening (MAST- PROPHYLAXIS).
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
You can take part if:
You may not be able to take part if:
MAST-DURATION: 1. Un-survivable injury2. Previous history of epilepsy3. Patients who are on an AED pre-TBI4. Patient who has been clinically prescribed an AED to treat PTS (other than phenytoin or levetiracetam) since current admission5. Any hypersensitivity to study drug selected or any of its excipients
MAST-PROPHYLAXIS:1. Post-traumatic seizures2. Unsurvivable injury3. Previous history of epilepsy4. Patients who are on an AED pre-TBI5. Pregnancy or breastfeeding6. Any hypersensitivity to study drug (or hydantoins or pyrrolidone derivatives) or any of its excipients 7. Time interval from the time of admission to NSU to randomisation exceeds 48 hours
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Dr
Samantha
Lawes
+44 (0)1223 256624
samantha.lawes@addenbrookes.nhs.uk
Prof
Peter
Hutchinson
+44 (0)1223 336946
pjah2@cam.ac.uk
More information about this study, what is involved and how to take part can be found on the study website.
The study is sponsored by Cambridge University Hospitals NHS Foundation Trust; University of Cambridge and funded by National Institute for Health Research.
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Or CPMS 46732
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
